GlobeNewswire: Auven Therapeutics Contains the last 10 of 6 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:29:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/01/06/904019/0/en/Auven-Therapeutics-Announces-Closing-of-Sale-of-Ocular-Technologies-Sarl-Holding-Entity-for-Seciera-for-Treatment-of-Dry-Eye-Disease.html?f=22&fvtc=4&fvtv=27695Auven Therapeutics Announces Closing of Sale of Ocular Technologies Sarl, Holding Entity for Seciera™ for Treatment of Dry Eye Disease2017-01-06T13:18:02Z<![CDATA[Achievement of primary endpoint of increased tear production and key secondary endpoints in confirmatory Phase 3 clinical trial highlights Seciera’s™ competitive value proposition, validates Auven’s investment model Achievement of primary endpoint of increased tear production and key secondary endpoints in confirmatory Phase 3 clinical trial highlights Seciera’s™ competitive value proposition, validates Auven’s investment model ]]>https://www.globenewswire.com/news-release/2016/10/26/883163/0/en/Auven-Therapeutics-Announces-Sale-of-Ocular-Technologies-to-Sun-Pharma.html?f=22&fvtc=4&fvtv=27695Auven Therapeutics Announces Sale of Ocular Technologies to Sun Pharma2016-10-26T15:38:29Z<![CDATA[Ocular Technologies’ key development program asset, SecieraTM for the treatment of dry eye disease, is close to completing confirmatory Phase 3 clinical trial]]>https://www.globenewswire.com/news-release/2016/08/22/865822/0/en/Auven-Therapeutics-Announces-Completion-of-Enrollment-in-Confirmatory-Phase-3-Clinical-Trial-of-Seciera-OTX-101-for-the-Treatment-of-Dry-Eye-Disease.html?f=22&fvtc=4&fvtv=27695Auven Therapeutics Announces Completion of Enrollment in Confirmatory Phase 3 Clinical Trial of Seciera (OTX‑101) for the Treatment of Dry Eye Disease2016-08-22T11:30:00Z<![CDATA[Pivotal study to confirm significant improvements in tear production and ocular surface inflammation in patients with dry eye disease, with top-line results anticipated by year-end]]>https://www.globenewswire.com/news-release/2016/03/03/816596/0/en/Auven-Therapeutics-Announces-Initiation-of-Confirmatory-Phase-3-Clinical-Trial-of-Seciera-OTX-101-for-the-Treatment-of-Dry-Eye-Disease.html?f=22&fvtc=4&fvtv=27695Auven Therapeutics Announces Initiation of Confirmatory Phase 3 Clinical Trial of Seciera (OTX‑101) for the Treatment of Dry Eye Disease2016-03-03T13:16:22Z<![CDATA[Study to confirm significant improvements in tear production as sole primary endpoint to support regulatory filing]]>https://www.globenewswire.com/news-release/2016/01/21/803624/0/en/Auven-Therapeutics-and-Bellus-Health-Announce-Completion-of-Pivotal-Phase-3-Confirmatory-Trial-of-KIACTA-for-the-Treatment-of-Orphan-Disease-AA-Amyloidosis.html?f=22&fvtc=4&fvtv=27695Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA™ for the Treatment of Orphan Disease AA Amyloidosis2016-01-21T13:00:00Z<![CDATA[Study Reached 120 Qualifying Events, Top-Line Results Expected in Q2 2016 Study Reached 120 Qualifying Events, Top-Line Results Expected in Q2 2016]]>https://www.globenewswire.com/news-release/2015/11/13/787027/10156193/en/Auven-Therapeutics-Announces-Positive-Results-From-Pivotal-Clinical-Trial-of-Seciera-OTX-101-in-Dry-Eye-Disease.html?f=22&fvtc=4&fvtv=27695Auven Therapeutics Announces Positive Results From Pivotal Clinical Trial of Seciera (OTX-101) in Dry Eye Disease2015-11-13T12:30:00Z<![CDATA[Seciera demonstrated significant improvements in tear production and ocular surface inflammation]]>